+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Herceptin"

Trastuzumab Biosimilars Global Market Report 2024 - Product Thumbnail Image

Trastuzumab Biosimilars Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
From
Breast Cancer Diagnostic and Drug Technologies: Global Markets - Product Thumbnail Image

Breast Cancer Diagnostic and Drug Technologies: Global Markets

  • Report
  • November 2019
  • 150 Pages
  • Global
From
From
Trastuzumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Trastuzumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Bevacizumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Bevacizumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
From
From
From
Investigation Report on Trastuzumab in China, 2018-2022 - Product Thumbnail Image

Investigation Report on Trastuzumab in China, 2018-2022

  • Report
  • June 2018
  • 30 Pages
  • China
From
From
Herceptin- Drug Insight, 2019 - Product Thumbnail Image

Herceptin- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 17 Results (Page 1 of 1)
Loading Indicator

Herceptin is a monoclonal antibody used to treat certain types of breast and gastric cancer. It is also used in the treatment of non-small cell lung cancer (NSCLC). Herceptin works by targeting the HER2 protein, which is found in higher levels in some types of cancer cells. This helps to slow down or stop the growth of cancer cells. Herceptin is used in combination with chemotherapy and other drugs to treat NSCLC. Herceptin is a relatively new drug in the lung cancer market, but it has been shown to be effective in treating certain types of NSCLC. It is generally well-tolerated and has fewer side effects than other treatments. Herceptin is also used in combination with other drugs to treat metastatic NSCLC, which is when the cancer has spread to other parts of the body. Herceptin is available in both generic and brand-name versions. It is typically administered intravenously in a hospital or clinic setting. Some companies in the Herceptin market include Genentech, Roche, Merck, and Pfizer. Show Less Read more